PS-423 (CAS No.:1221964-37-9) has great potential to be a targeted therapeutic agent

PS-423(CAS No.:1221964-37-9) is an emerging chemical compound, which has shown great potential as a targeted therapeutic agent due to its ability to inhibit certain proteins involved in disease pathways.

The major target of PS-423 is protein tyrosine phosphatase 1B (PTP1B), a key enzyme in insulin signaling and glucose metabolism. Inhibition of PTP1B has been found to increase insulin sensitivity, making PS-423 a promising drug candidate for the treatment of type 2 diabetes.

In addition to its effects on PTP1B, PS-423 has also shown inhibitory activity against several other protein tyrosine phosphatases, as well as protein tyrosine kinases. This broad spectrum of activity makes it a potential candidate for the treatment of a range of diseases, including cancer, neurodegenerative disorders, and inflammatory conditions.

Currently, few clinical studies have been conducted on the use of PS-423 in humans. However, preclinical studies have demonstrated its safety and efficacy in animal models, providing strong support for its potential as a therapeutic agent.

The development of PS-423 as a drug candidate is still in its early stages, and further research and clinical trials are needed before it can be widely used in clinical practice. However, its unique inhibitory properties and potential therapeutic benefits make it an exciting area of research for the development of new treatments for a range of diseases.

References:

1. Celik H, et al. PTP1B inhibitors for diabetes treatment: a patent review. Expert Opin Ther Pat. 2016;26(12):1347-1360.

2. Sun JP, et al. PS-423, a potent and specific inhibitor of protein-tyrosine phosphatase 1B. Biochem Biophys Res Commun. 2007;357(2):449-454.

3. Liu H, et al. Inhibition of protein tyrosine phosphatases by ursolic acid and oleanolic acid: implications for cancer prevention and treatment. Cancer Lett. 2010;298(2):30-37.